Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 5.36 is 57% below its 5-year average of 12.54, near the low end of its 5-year range (5.28–20.27).
As of the fiscal period ended Tuesday, June 30, 2026. 25.22% below its 12-month average of 7.16.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.36.
CURRENT RATIO
5.36
CURRENT RATIO AVG TTM
7.16
CURRENT RATIO AVG 3Y
11.30
CURRENT RATIO AVG 5Y
12.54
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-25.22%
CURRENT VS 3Y AVG
-52.61%
CURRENT VS 5Y AVG
-57.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+42.84%
vs the sector median at left
Lyell Immunopharma, Inc.
Market Cap
$210.98M
Current Ratio
5.36
TTM Avg
7.16
3Y Avg
11.30
5Y Avg
12.54
Market Cap
$210.41M
Current Ratio
10.89
TTM Avg
11.84
3Y Avg
8.89
5Y Avg
15.32
Market Cap
$214.46M
Current Ratio
20.05
TTM Avg
17.55
3Y Avg
12.54
5Y Avg
12.54
Market Cap
$215.07M
Current Ratio
344.31
TTM Avg
177.51
3Y Avg
95.19
5Y Avg
76.57
Market Cap
$205.80M
Current Ratio
17.38
TTM Avg
6.92
3Y Avg
7.03
5Y Avg
6.44
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $210.98M | 5.36 | 7.16 | 11.30 | 12.54 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | 10.89 | 11.84 | 8.89 | 15.32 |
| Compugen Ltd. (CGEN)vs › | $209.91M | 5.72 | 5.91 | 5.85 | 7.15 |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 6.50 | 4.21 | 3.36 | 3.03 |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | 20.05 | 17.55 | 12.54 | 12.54 |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 4.10 | 3.67 | 3.34 | 3.14 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 344.31 | 177.51 | 95.19 | 76.57 |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | 17.38 | 6.92 | 7.03 | 6.44 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | 4.07 | 3.65 | 6.88 | 10.38 |
Current Ratio
5.36
Quick Ratio
5.36
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 5.36 |
| 2026-03-31 | 7.23 |
| 2025-12-31 | 5.28 |
| 2025-09-30 | 10.30 |
| 2025-06-30 | 7.65 |
| 2025-03-31 | 7.49 |
| 2024-12-31 | 7.06 |
| 2024-09-30 | 13.43 |
| 2024-06-30 | 16.19 |
| 2024-03-31 | 16.51 |
| 2023-12-31 | 16.07 |
| 2023-09-30 | 16.74 |
| 2023-06-30 | 17.63 |
| 2023-03-31 | 20.27 |
| 2022-12-31 | 17.59 |
| 2022-09-30 | 12.88 |
| 2022-06-30 | 13.26 |
| 2022-03-31 | 15.24 |
| 2021-12-31 | 13.40 |
| 2021-09-30 | 10.65 |
| 2021-06-30 | 13.11 |
| 2021-03-31 | 10.73 |
| 2020-12-31 | 12.53 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
